Grace Therapeutics Announces $10 Million Private Placement
Grace Therapeutics announced a $10 million private placement financing priced at-the-market on Nasdaq to support manufacturing and regulatory efforts for its lead clinical asset, GTx-104, an injectable formulation of nimodipine for IV infusion aimed at treating aneurysmal subarachnoid hemorrhage (aSAH). The company is pursuing a dual-source manufac…